President Trump just locked in prescription drug pricing deals projected to save Americans $600 billion — and the pharmaceutical lobby is already working overtime to explain why that's somehow bad for you.

For decades, American consumers have subsidized the rest of the developed world's cheap drugs while paying the highest prices on earth at their own pharmacy counters. The new "most favored nation" agreements, now covering 26 drugmakers and 89% of the branded drug market, force companies to charge Medicaid what they charge foreign governments. It's straightforward: if France gets a deal, your state should too.

The numbers tell the story. U.S. prescription drug prices average nearly three times what other developed nations pay, according to a 2024 Rand Corp. study — and for branded drugs, more than four times higher. Trump put it bluntly from the Oval Office: "We were ripped off by the pharmaceutical companies, and we were ripped off more than anything by other countries throughout the world." He noted the U.S. consumes just 13% of prescription drugs globally but accounts for 75% of pharma profits. That's not a market. That's a shakedown.

The deals work by tying Medicaid outpatient drug prices to the lowest prices those same companies charge abroad. In exchange, manufacturers get shielded from pharmaceutical tariffs. CNBC reported the companies will also be exempted from pilot programs mandating similar discounts in Medicare. It's a carrot-and-stick approach — and it's producing results. Drugmakers like Novo Nordisk are now spending billions to bring manufacturing back to U.S. soil to insulate themselves from tariff threats, and they're expanding direct-to-consumer channels including the administration's TrumpRx portal.

Naturally, the industry isn't celebrating. PhRMA, the trade group representing the biggest pharmaceutical companies, has pushed back, claiming most-favored-nation pricing "isn't the best way" to lower costs and pointing fingers at pharmacy benefit managers instead. Notice what's missing from that argument: any actual alternative that would cut prices by the same magnitude. CNBC also noted that since Medicaid already receives steep discounts under federal law, it's "unclear" how the new deals will affect what patients actually pay out of pocket. Fair point — and worth watching. The real test is whether these savings reach the cash register or get absorbed somewhere in the supply chain.

But here's what the skeptics don't want to grapple with: something is finally moving. Trump said he "lost some very good friends" pushing this fight. When a politician loses friends in the lobbying corridor and working families save money, that's called doing the job. The pharmaceutical industry has poured staggering sums into Washington to maintain a pricing system that treats American patients as the world's ATM. Both parties had years to fix it. They didn't.

The question isn't whether $600 billion in projected savings will materialize down to the last dollar. The question is why it took this long for any president to demand that Americans stop subsidizing the world's medicine cabinet — and who, exactly, is still arguing they should.